

Review Article

Integrative Machine Learning Approaches for Predicting Metformin Response in Type 2 Diabetes: A Multi-Omics Perspective

K. Chandramohan¹, R. Nepolean², V. Balaji^{3*}, D. Anbarasu⁴, N. Jayaram⁵

From, ¹Vice Principal & Professor and Head, ²Professor and Principal, ³PG Student, ⁴Associate Professor, ⁵Assistant Professor, Department of Pharmaceutics, Thanthai Roever College of Pharmacy, The Tamilnadu Dr. M.G.R. Medical University, India.

ABSTRACT

Background: Type 2 Diabetes Mellitus is a heterogeneous metabolic disorder characterized by variable therapeutic responses. Metformin remains the first-line therapy; however, significant interindividual variability in glycemic response limits its effectiveness. **Objective:** To review and synthesize current evidence on integrative machine learning approaches that combine multi-omics and clinical data to predict metformin response in individuals with Type 2 Diabetes. **Methods:** A comprehensive narrative review was conducted, focusing on studies integrating pharmacogenomic, metabolomic, and clinical datasets using machine learning techniques such as Random Forest, Support Vector Machines, and neural networks. Data integration strategies including early, intermediate, and late fusion were examined. **Results:** Individual predictors, including genetic variants (e.g., SLC22A1, ATM), clinical factors (age, BMI, baseline HbA1c), and metabolomic signatures (amino acids, lipids, gut-derived metabolites), explain only a fraction of variability in metformin response. Integrative machine learning models demonstrate improved predictive performance by capturing nonlinear interactions across biological layers. However, challenges such as data heterogeneity, small sample sizes, lack of standardization, and limited external validation persist. **Conclusion:** Multi-omics integration using machine learning offers a promising pathway toward precision medicine in Type 2 Diabetes. Nevertheless, methodological limitations, interpretability issues, and translational barriers must be addressed before clinical implementation.

Key words: Type 2 Diabetes Mellitus, Metformin, Machine Learning, Pharmacogenomics, Metabolomics, Precision Medicine, Multi-Omics Integration, Artificial Intelligence

Type 2 Diabetes (T2D) has emerged as a major global health concern, with rapidly rising prevalence and substantial socioeconomic burden [1,2]. Characterized by insulin resistance and progressive pancreatic β -cell dysfunction, T2D is associated with long-term complications including cardiovascular disease, nephropathy, neuropathy, and retinopathy [2,3]. Despite advances in therapeutic strategies, achieving durable glycemic control remains challenging, reflecting the heterogeneous nature of the disease and variability in treatment response among individuals [4]. Metformin is widely recommended as the first-line pharmacological therapy for T2D owing to its efficacy, safety, and affordability [5,6].

Its primary glucose-lowering effects are mediated through suppression of hepatic gluconeogenesis and activation of AMP-activated protein kinase (AMPK), along with emerging roles in modulating gut microbiota and systemic metabolism [7,8]. However, considerable interindividual variability in metformin response has been consistently reported, with a

significant subset of patients failing to achieve adequate glycemic control or experiencing adverse effects [9,10].

This variability underscores a critical limitation of the current “one-size-fits-all” treatment paradigm. The determinants of metformin response are multifactorial, encompassing genetic variation, clinical characteristics, and metabolic state. Pharmacogenomic studies have identified variants in genes involved in drug transport and action, such as SLC22A1 and ATM, which influence metformin pharmacokinetics and pharmacodynamics [11–13].

Concurrently, clinical factors including age, body mass index, renal function, and baseline glycemic status are routinely used to guide therapeutic decisions but provide only limited predictive accuracy [14–16]. More recently, metabolomics has offered insights into dynamic biochemical signatures associated with treatment response, capturing downstream effects of both genetic and environmental influences [17,18]. However, each of these domains, when considered in isolation, explains only a fraction of the

Access this article online

Received – 25th April 2026
Initial Review – 02nd May 2026
Accepted – 19th May 2026

Quick Response Code



Correspondence to: V. Balaji, Department of Pharmaceutics Thanthai Roever College of Pharmacy Perambalur – 621212, Tamil Nadu, India

Email: balajibala68760@gmail.com

observed variability. The integration of multi-dimensional data represents a promising approach to address this complexity. Advances in high-throughput technologies and computational methods have enabled the simultaneous analysis of pharmacogenomic, clinical, and metabolomic data.

In parallel, machine learning (ML) techniques have demonstrated the capacity to model nonlinear relationships and interactions across heterogeneous datasets, offering improved predictive performance compared to traditional statistical approaches. Nevertheless, challenges related to data integration, model interpretability, reproducibility, and clinical translation remain substantial. In this review, we critically examine integrative machine learning approaches that combine pharmacogenomic, clinical, and metabolomic data to predict metformin response in T2D. We evaluate current evidence, compare data integration strategies, and highlight key methodological and translational challenges. Furthermore, we discuss future directions for developing robust, interpretable, and clinically applicable models to advance precision medicine in diabetes care.

2. BIOLOGICAL BASIS OF METFORMIN RESPONSE VARIABILITY

The glucose-lowering effects of Metformin are mediated through a combination of hepatic, intestinal, and peripheral mechanisms, with AMP-activated protein kinase (AMPK) playing a central regulatory role [19,20]. Metformin inhibits hepatic gluconeogenesis primarily by altering cellular energy status, leading to increased AMP/ATP ratios and subsequent activation of AMPK [21,22].

This results in suppression of key gluconeogenic enzymes and reduced hepatic glucose output. In addition, metformin modulates mitochondrial respiratory chain complex I activity, contributing to decreased ATP production and reinforcing its inhibitory effect on gluconeogenesis[23,24]. Beyond hepatic actions, metformin enhances peripheral insulin sensitivity and influences intestinal glucose absorption, highlighting its multi-organ mode of action. Despite these well-characterized mechanisms, substantial interindividual variability in therapeutic response remains, reflecting the influence of multiple biological layers (Figure 1).




Figure 1. Multi-organ mechanisms of metformin action in Type 2 Diabetes. (AMPK, AMP-activated protein kinase; GLP-1, glucagon-like peptide-1; G6Pase, glucose-6-phosphatase; GLUT4, glucose transporter type 4; HbA1c, glycated haemoglobin; OCT1, organic cation transporter 1 (SLC22A1); PGC-1 α , peroxisome proliferator-activated receptor gamma coactivator 1-

alpha; PEPCCK, phosphoenolpyruvate carboxykinase; SCFA, short-chain fatty acid; SGLT1, sodium–glucose cotransporter 1; TORC2, transducer of regulated CREB activity 2).

Genetic Determinants of Drug Transport and Action

Genetic variability significantly influences metformin pharmacokinetics and pharmacodynamics, particularly through genes encoding membrane transporters. Among these, SLC22A1, which encodes the organic cation transporter 1 (OCT1), plays a critical role in hepatic uptake of metformin. Reduced-function variants in this gene can impair intracellular drug accumulation, thereby attenuating its glucose-lowering

effects [25–27]. Additional transporters, including SLC47A1 (MATE1) and SLC22A2 (OCT2), regulate metformin excretion and distribution, further contributing to variability in systemic exposure [28]. However, while these genetic associations are mechanistically plausible, their individual effect sizes are modest and insufficient to fully explain clinical heterogeneity. This suggests that genetic determinants act in concert with other biological and environmental factors rather than functioning as standalone predictors (Figure 2).




Figure 2. Multifactorial determinants of interindividual variability in metformin response. (AMPK, AMP-activated protein kinase; ATM, ataxia telangiectasia mutated; BCAA, branched-chain amino acid; GWAS, genome-wide association study; HbA1c, glycated haemoglobin; MATE1, multidrug and toxin extrusion protein 1; OCT1/2, organic cation transporter 1/2; SCFA, short-chain fatty acid; SLC22A1/A2, solute carrier family 22 member 1/2; SLC47A1, solute carrier family 47 member 1).

Gut Microbiome as a Modulator of Response

Emerging evidence highlights the gut microbiome as a key mediator of metformin efficacy. Metformin has been shown to alter the composition and functional capacity of intestinal microbial communities, promoting the enrichment of bacteria involved in short-chain fatty acid (SCFA) production [29,30]. These metabolites, in turn, influence host energy metabolism, inflammation, and insulin sensitivity. Importantly, baseline microbiome composition may determine the magnitude of

response to metformin. Interindividual differences in microbial diversity and metabolic activity can modulate drug bioavailability and downstream metabolic effects [31,32]. This bidirectional interaction between metformin and the microbiome introduces an additional layer of complexity that is not captured by host genomic or clinical data alone.

Influence of Baseline Metabolic State

The metabolic phenotype of an individual plays a crucial role in shaping response to metformin. Variations in insulin

resistance, hepatic lipid content, and circulating metabolites such as branched-chain amino acids and lipid species, can influence drug efficacy [33,34]. Patients with distinct metabolic profiles may exhibit differential activation of pathways targeted by metformin, leading to variability in therapeutic outcomes [35]. Unlike genetic factors, metabolic states are dynamic and reflect the combined effects of lifestyle, environment, and disease progression [36]. This dynamic nature makes metabolomic profiling particularly valuable for capturing real-time physiological status and predicting treatment response.

3. PHARMACOGENOMICS OF METFORMIN

Pharmacogenomics has been extensively explored as a strategy to explain interindividual variability in response to Metformin in patients with Type 2 Diabetes. Given that metformin is not metabolized and relies on membrane transporters for absorption, distribution, and excretion, genetic variation in transporter and signaling genes plays a central role in modulating its pharmacokinetics and pharmacodynamics.

Key Genes and Molecular Pathways

Among the most extensively studied genes is SLC22A1, which encodes the organic cation transporter 1 (OCT1), a key determinant of hepatic uptake of metformin [27,37]. Reduced-function variants in SLC22A1 have been associated with decreased intracellular drug accumulation and attenuated glucose-lowering effects[38]. However, findings across studies have been inconsistent, with some cohorts showing significant associations and others reporting minimal or no effect.

Another gene of interest is ATM (ataxia telangiectasia mutated), identified through genome-wide association studies (GWAS) as being associated with glycemic response to metformin [39,40]. ATM is implicated in cellular stress responses and may influence AMPK activation, although the precise biological mechanisms linking ATM variants to metformin efficacy remain incompletely understood. Additional transporters, including SLC47A1 (encoding MATE1) and SLC22A2 (encoding OCT2), contribute to renal elimination and systemic exposure of metformin[41]. Variants in these genes can affect drug clearance and plasma concentrations, further contributing to interindividual variability. Collectively, these genetic factors highlight the importance of drug transport and intracellular signaling pathways in determining metformin response.

Insights from Genome-Wide Association Studies

GWAS have provided a hypothesis-free approach to identifying genetic loci associated with metformin response [42]. Several loci, including variants near ATM, have been linked to differences in glycemic outcomes, typically measured as changes in HbA1c following treatment initiation [43,44]. These studies have expanded the scope of investigation beyond candidate genes and uncovered novel biological pathways potentially involved in drug response.

However, the reproducibility of GWAS findings has been limited. Many associations fail to replicate across independent cohorts, reflecting differences in study design, sample size, phenotype definition, and population structure. Moreover, identified variants often reside in non-coding regions, making it challenging to elucidate their functional significance (Figure 3).




Figure 3. Membrane transporter-mediated pharmacokinetics of metformin and intracellular AMPK signalling.

4. CLINICAL PREDICTORS OF METFORMIN RESPONSE

Clinical characteristics remain the most accessible and widely used predictors of therapeutic response to Metformin in patients with Type 2 Diabetes. These variables are routinely captured in clinical practice and form the basis of conventional treatment decisions. However, while clinically informative, their predictive capacity is inherently limited by their inability to capture underlying molecular heterogeneity.

Demographic and Physiological Factors

Age is a key determinant of metformin response, reflecting age-related changes in insulin sensitivity, β -cell function, and comorbidity burden [45]. Older individuals often exhibit reduced renal function and altered pharmacokinetics, which can influence both efficacy and tolerability [46]. However, the relationship between age and glycemic response is not linear and may be confounded by disease duration and treatment history. Body mass index (BMI) is another commonly evaluated predictor, given its association with insulin resistance [47]. Patients with higher BMI often demonstrate greater insulin resistance and may exhibit more pronounced absolute reductions in glycemic parameters following metformin therapy [48].

Nevertheless, BMI is a crude surrogate for metabolic health and does not adequately distinguish between adipose tissue distribution, ectopic fat accumulation, or underlying metabolic phenotypes. Renal function plays a critical role in metformin pharmacokinetics, as the drug is primarily excreted unchanged via the kidneys [49]. Impaired renal function can lead to increased systemic exposure, necessitating dose adjustments and influencing therapeutic outcomes. While renal parameters are essential for safety considerations, their role in predicting glycemic response is less clearly defined.

Baseline Glycemic Status

Baseline glycated hemoglobin (HbA1c) is one of the most consistent clinical predictors of metformin response [50,51]. Patients with higher baseline HbA1c levels typically experience greater absolute reductions following treatment initiation, a phenomenon partly attributable to regression to the mean and a larger margin for improvement [52]. However, reliance on baseline HbA1c as a predictive marker has limitations. It reflects cumulative glycemic exposure rather than underlying pathophysiology and does not account for differences in insulin resistance, β -cell function, or metabolic flexibility. Consequently, while useful for estimating treatment effect size, HbA1c alone provides limited mechanistic insight.

Influence of Comorbidities

Comorbid conditions including cardiovascular disease, hepatic dysfunction, and obesity-related complications, can significantly influence metformin response [53]. For example, hepatic steatosis may alter gluconeogenic pathways targeted

by metformin, while cardiovascular comorbidities often coexist with systemic metabolic dysregulation. In addition, concomitant medications used to manage comorbidities may interact with metformin pharmacokinetics or modify metabolic pathways, further complicating prediction of treatment outcomes. These interactions highlight the complexity of real-world clinical settings, where multiple factors simultaneously influence drug response.

5. METABOLOMICS AND BIOMARKER SIGNATURES

Metabolomics provides a comprehensive, functional readout of biochemical activity, capturing downstream effects of genetic variation, environmental exposure, and disease progression [54]. In the context of Type 2 Diabetes, metabolomic profiling has emerged as a powerful approach to identify biomarkers associated with therapeutic response to Metformin. Unlike genomic data, which reflect static predisposition, metabolomic signatures are dynamic and closely aligned with the current physiological state, making them particularly relevant for predicting drug efficacy [55].

Analytical Platforms: LC–MS and NMR

The two principal analytical platforms used in metabolomics are liquid chromatography–mass spectrometry (LC–MS) and nuclear magnetic resonance (NMR) spectroscopy [56,57]. LC–MS offers high sensitivity and broad metabolite coverage, enabling detection of low-abundance compounds across diverse biochemical classes. It is particularly well-suited for lipidomics and targeted metabolite profiling [56].

In contrast, NMR spectroscopy provides highly reproducible and quantitative measurements with minimal sample preparation, although it is less sensitive than LC–MS. NMR is advantageous for untargeted metabolomics and longitudinal studies due to its robustness and consistency [57]. Despite their complementary strengths, variability in sample handling, instrument calibration, and data processing across studies poses challenges for standardization and reproducibility. These technical considerations are critical when interpreting metabolomic biomarkers in the context of drug response.

Amino Acid Signatures

Alterations in amino acid metabolism, particularly involving branched-chain amino acids (BCAAs) such as leucine, isoleucine, and valine, have been consistently associated with insulin resistance and T2D progression [58]. Elevated baseline levels of BCAAs have been linked to reduced responsiveness to metformin, potentially reflecting impaired metabolic flexibility [59]. Other amino acids, including glycine and glutamine, have been implicated in modulating glucose metabolism and may serve as indicators of treatment response. These findings suggest that amino acid profiles capture key aspects of metabolic dysfunction that influence the efficacy of metformin.

Lipidomic Profiles

Lipid metabolism plays a central role in insulin sensitivity and energy homeostasis, making lipidomic signatures particularly relevant for predicting metformin response [60]. Variations in circulating lipid species, including triglycerides, phospholipids, and sphingolipids, have been associated with differential treatment outcomes [61]. For instance, elevated levels of certain lipid intermediates may reflect lipotoxicity and mitochondrial dysfunction, potentially attenuating the therapeutic effects of metformin [62]. Conversely, improvements in lipid profiles following treatment may indicate favorable metabolic adaptation. These observations highlight the importance of lipid metabolism as both a determinant and a marker of drug response.

Gut-Derived Metabolites

The gut microbiome contributes to host metabolism through the production of bioactive metabolites, including short-chain fatty acids (SCFAs), bile acids, and other microbial-derived compounds [63]. Metformin has been shown to alter microbial composition and function, leading to changes in these metabolite profiles [29]. SCFAs, such as acetate and butyrate, are of particular interest due to their roles in regulating glucose homeostasis, inflammation, and energy balance [64]. Variability in baseline levels of gut-derived metabolites and microbiome composition may influence individual responses to metformin, providing a mechanistic link between microbial ecology and drug efficacy.

6. MACHINE LEARNING IN PREDICTING DRUG RESPONSE

Machine learning (ML) approaches have gained prominence in modeling interindividual variability in response to Metformin for patients with Type 2 Diabetes [65]. Unlike traditional statistical models that assume linearity and limited interactions, ML methods can capture complex, nonlinear relationships across high-dimensional datasets, making them particularly well-suited for integrating clinical and multi-omics data [66].

Random Forest

Random Forest (RF) is an ensemble learning method that constructs multiple decision trees using bootstrap sampling and aggregates their predictions [67]. It is widely used in biomedical applications due to its robustness to noise and ability to handle high-dimensional data.

In the context of metformin response prediction, RF models are particularly effective for:

- Capturing nonlinear relationships between predictors and outcomes
- Identifying feature importance, which can provide biological insight
- Handling mixed data types (clinical + omics)

However, RF models may become biased toward variables with more categories or higher variance, and their interpretability, while better than some deep learning methods, remains limited at the individual prediction level [68].

Support Vector Machines

Support Vector Machines (SVM) are supervised learning algorithms that identify an optimal hyperplane to separate classes in high-dimensional space. By employing kernel functions, SVMs can model complex nonlinear decision boundaries [69].

SVMs are particularly advantageous in:

- High-dimensional, low-sample-size settings, common in omics datasets
- Situations requiring clear decision boundaries
- Reducing overfitting through margin maximization

Despite these strengths, SVMs are sensitive to kernel choice and parameter tuning, and their outputs are less interpretable compared to tree-based models. Additionally, scaling SVMs to very large datasets can be computationally demanding [70].

Neural Networks

Artificial neural networks (ANNs), including deep learning architectures, have shown increasing promise in modeling complex biomedical data. These models can automatically learn hierarchical feature representations, making them particularly suitable for multi-omics integration [71].

In predicting drug response, neural networks offer:

- Superior ability to model complex, nonlinear interactions
- Flexibility in handling multi-modal data inputs
- Potential for end-to-end learning without manual feature engineering

However, these advantages come at a cost. Neural networks typically require large datasets to achieve generalizable performance, which are often unavailable in clinical research. Furthermore, they are frequently criticized as “black-box” models, limiting their interpretability and clinical trust [72].

7. MULTI-OMICS INTEGRATION STRATEGIES

The integration of pharmacogenomic, clinical, and metabolomic data represents a critical step toward improving prediction of therapeutic response to Metformin in Type 2 Diabetes. However, the effectiveness of such integrative approaches depends heavily on the chosen data fusion strategy. Broadly, multi-omics integration can be categorized into early fusion (feature-level), late fusion (model-level), and intermediate fusion (hybrid/deep learning-based approaches), each with distinct advantages and limitations.

Early Fusion (Feature-Level Integration)

Early fusion involves concatenating features from multiple data sources into a single unified feature matrix prior to model training [73]. For example, genetic variants, clinical variables, and metabolite concentrations are combined and used as input to a single machine learning model. This approach offers several advantages. It enables the model to directly learn interactions across data types, potentially capturing synergistic effects between genetic, metabolic, and clinical factors. It is also relatively straightforward to implement and compatible with a wide range of machine learning algorithms, including Random Forest and Support Vector Machines [74]. However, early fusion is highly sensitive to data heterogeneity and scaling issues. Differences in data dimensionality such as thousands of genomic features versus a limited number of clinical variables, can bias model learning [75]. Additionally, missing data across modalities can significantly reduce usable sample size. Without careful preprocessing and feature selection, early fusion models are prone to overfitting, particularly in small cohorts typical of biomedical studies.

Late Fusion (Model-Level Integration)

Late fusion adopts a modular approach, where separate models are trained independently on each data modality, and their outputs are subsequently combined (e.g., via averaging, voting, or meta-learning) [76]. This strategy offers improved flexibility and robustness, as each model can be optimized for its specific data type. It also mitigates issues related to missing data, since predictions can still be generated from available

modalities. Importantly, late fusion enhances interpretability by allowing assessment of the contribution of each data source to the final prediction [77]. However, a key limitation is that late fusion may fail to fully capture cross-modal interactions, as relationships between features from different data types are not explicitly modeled during training. As a result, its predictive performance may be inferior in scenarios where such interactions are biologically important [78].

Intermediate Fusion (Hybrid / Deep Learning Approaches)

Intermediate fusion represents a more advanced strategy, often implemented deep learning architectures, where each data modality is first processed separately to learn latent representations, which are then integrated at a later stage within the model [79]. This approach balances the strengths of early and late fusion. By learning modality-specific representations, it can handle heterogeneous data more effectively, while still enabling cross-modal interactions at deeper layers. Intermediate fusion is particularly well-suited for complex, high-dimensional datasets and has shown promising performance in recent multi-omics studies [80,81]. Nevertheless, these methods come with significant challenges. They typically require large datasets to avoid overfitting, which are often unavailable in clinical research. Furthermore, deep learning models are frequently criticized for their lack of interpretability, posing barriers to clinical adoption. Implementation complexity and computational demands also limit their widespread use (Figure 4).




Figure 4. Comparative overview of multi-omics data integration strategies for metformin response prediction.

8. CURRENT STUDIES AND EVIDENCE

Recent studies have increasingly explored the use of machine learning and multi-omics approaches to predict variability in response to Metformin in Type 2 Diabetes. While the field remains relatively nascent, emerging evidence highlights the complementary value of integrating pharmacogenomic, metabolomic, and clinical data.

Genomics and Clinical Models

Early predictive models primarily combined pharmacogenomic variants with clinical features such as HbA1c, BMI, and age [82]. Studies focusing on transporter genes (e.g., SLC22A1, SLC47A1) and loci identified through genome-wide association studies (GWAS), such as ATM, demonstrated modest improvements in prediction accuracy when combined with clinical variables [12,83,84]. However, these models typically explain only a small proportion of variability in glycemic response, reflecting the limited effect size of individual genetic variants and the inability of such models to capture downstream metabolic dynamics.

Metabolomics and Machine Learning Approaches

More recent studies have shifted toward metabolomics-driven prediction, often leveraging machine learning techniques [85,86]. Metabolomic profiling enables identification of biochemical signatures associated with drug response, aligning closely with the concept of pharmacometabolomics, which links metabolic state to pharmacological outcomes [87,88]. Machine learning models applied to metabolomic datasets have demonstrated improved predictive performance compared to traditional statistical methods, particularly in capturing nonlinear relationships among metabolites and clinical variables [89]. For example, automated ML approaches in metabolic profiling have identified novel metabolite associations with metformin exposure, suggesting the potential of data-driven biomarker discovery. Despite these advances, many studies remain limited by small sample sizes and lack of external validation, raising concerns regarding generalizability.

Multi-Omics Integration Models

The most recent and promising developments involve the integration of multiple omics layers using advanced computational frameworks. Multi-omics approaches combine genomic, metabolomic, and sometimes transcriptomic or proteomic data to capture the full biological context of drug response [90]. Such integrative models have demonstrated improved predictive accuracy by capturing interactions across biological layers, revealing pathways related to insulin signaling, inflammation, and energy metabolism that are not identifiable using single-omics approaches [91]. AI-driven multi-omics frameworks further enhance predictive capabilities by leveraging deep learning and representation learning techniques to identify hidden patterns across heterogeneous datasets [92]. However, evidence remains

fragmented, with variability in study design, data types, and validation strategies limiting direct comparison across studies.

9. CHALLENGES AND LIMITATIONS

Despite growing enthusiasm for integrative machine learning approaches to predict response to Metformin in Type 2 Diabetes, several fundamental challenges limit their reliability, generalizability, and clinical translation, stemming from issues in data generation, study design, and healthcare implementation [93]. Multi-omics datasets are inherently heterogeneous, with genomic data being high-dimensional and stable, metabolomic profiles dynamic and environmentally sensitive, and clinical data often sparse and inconsistently recorded, complicating integration and introducing bias through differing preprocessing and normalization methods, which reduces model generalizability[94].

Missing data further complicates analysis, as incomplete datasets across modalities are common and often non-random, making traditional deletion methods impractical and imputation potentially biased, while many models lack robustness to such gaps [95]. The absence of standardized protocols in data collection, processing, and phenotype definitions such as varying measures of metformin response, hinders reproducibility and comparability across studies [96]. Additionally, small cohort sizes relative to high-dimensional features increase the risk of overfitting and limit meaningful validation across diverse populations [97].

Reproducibility is further undermined by reliance on internal validation rather than independent datasets, inconsistent methodologies, and lack of transparency or data sharing. Finally, ethical and privacy concerns surrounding sensitive multi-omics data, including risks of re-identification, issues of consent and ownership, and underrepresentation of diverse populations, raise concerns about bias and fairness, potentially exacerbating existing healthcare disparities.

CONCLUSION

The variability in therapeutic response to Metformin in Type 2 Diabetes highlights the limitations of traditional single-layer predictive approaches, as pharmacogenomic, clinical, and metabolomic data individually capture only fragments of the underlying biological complexity. Integrative machine learning frameworks that combine these data modalities offer a more comprehensive strategy by modeling nonlinear relationships and cross-domain interactions, thereby improving predictive accuracy and providing deeper mechanistic insight.

However, despite promising advances, such approaches remain methodologically immature, constrained by challenges including data heterogeneity, limited cohort sizes, lack of standardization, and insufficient external validation. Furthermore, issues related to interpretability, reproducibility, and data governance continue to impede clinical translation.

Consequently, while multi-omics integration represents a significant step toward precision medicine, substantial methodological and translational barriers must be addressed before these models can be reliably implemented in routine clinical practice for managing Type 2 Diabetes.

REFERENCE

- Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of Type 2 Diabetes - Global Burden of Disease and Forecasted Trends. *J Epidemiol Glob Health* 2020;10:107–11. <https://doi.org/10.2991/jegh.k.191028.001>.
- Goyal R, Singhal M, Jialal I. Type 2 Diabetes. 2026.
- Dludla P V, Mabhidha SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, et al. Pancreatic β -cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. *World J Diabetes* 2023;14:130–46. <https://doi.org/10.4239/wjd.v14.i3.130>.
- Ahmed Y, Mohamed Abuelass FK, Hamd Abdelwahab SB, Mukhtar M, Ahmed Y, Elfahal M, et al. Determinants of Poor Glycemic Control Among Type 2 Diabetes Patients: A Systematic Review. *Cureus* 2025;17:e82464. <https://doi.org/10.7759/cureus.82464>.
- Corcoran C, Jacobs TF. Metformin. 2026.
- Lv Z, Guo Y. Metformin and Its Benefits for Various Diseases. *Front Endocrinol (Lausanne)* 2020;11:191. <https://doi.org/10.3389/fendo.2020.00191>.
- Sun D, Wang J, Li X, Peng J, Wang S. Advances and Perspectives in Curcumin Regulation of Systemic Metabolism: A Focus on Multi-Organ Mechanisms. *Antioxidants (Basel)* 2026;15. <https://doi.org/10.3390/antiox15010109>.
- Yibcharoenporn C, Muanprasat C, Moonwiriya A, Satitsri S, Pathomthongtaweethai N. AMPK in Intestinal Health and Disease: A Multifaceted Therapeutic Target for Metabolic and Inflammatory Disorders. *Drug Des Devel Ther* 2025;19:3029–58. <https://doi.org/10.2147/DDDT.S507489>.
- Anwardeen NR, Naja K, Elrayess MA. Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes. *Front Pharmacol* 2024;15. <https://doi.org/10.3389/fphar.2024.1506767>.
- Chaker F, Kallel A, Khessairi N, Yazidi M, Oueslati I, Chatti HA, et al. Metformin efficacy and tolerance according to genetic polymorphisms of organic cation transporter 1 in Tunisian patients with type 2 diabetes. *Front Endocrinol (Lausanne)* 2025;16:1536402. <https://doi.org/10.3389/fendo.2025.1536402>.
- Al-Eitan LN, Almomani BA, Nassar AM, Elsaqa BZ, Saadeh NA. Metformin Pharmacogenetics: Effects of SLC22A1, SLC22A2, and SLC22A3 Polymorphisms on Glycemic Control and HbA1c Levels. *J Pers Med* 2019;9. <https://doi.org/10.3390/jpm9010017>.
- Ningrum VDA, Sadewa AH, Ikawati Z, Yuliwulandari R, Ikhsan MR, Fajriyah R. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response. *PLoS One* 2022;17:e0271410. <https://doi.org/10.1371/journal.pone.0271410>.
- Saiz-Rodríguez M, Ochoa D, Zubiaur P, Navares-Gómez M, Román M, Camargo-Mamani P, et al. Identification of Transporter Polymorphisms Influencing Metformin Pharmacokinetics in Healthy Volunteers. *J Pers Med* 2023;13:489. <https://doi.org/10.3390/jpm13030489>.
- Deng L, Jia L, Wu X-L, Cheng M. Association Between Body Mass Index and Glycemic Control in Type 2 Diabetes Mellitus: A Cross-Sectional Study. *Diabetes Metab Syndr Obes* 2025;18:555–63. <https://doi.org/10.2147/DMSO.S508365>.
- Hu H, Mu X, Zhao S, Yang M, Zhou H. Development of Predictive Models for Progression from Diabetic Kidney Disease to End-Stage Renal Disease in Type 2 Diabetes Mellitus: A Retrospective Cohort Study. *Diabetes Metab Syndr Obes* 2025;18:383–98. <https://doi.org/10.2147/DMSO.S500992>.
- Cheng A, Huang C, Leu H, Yin W, Tseng W, Wu Y, et al. Glycemic control and renal function decline in patients with chronic coronary syndrome: A multicenter cohort study. *J Diabetes Investig* 2026. <https://doi.org/10.1111/jdi.70274>.
- Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J, et al. Metabolomics-driven approaches for identifying therapeutic targets in drug discovery. *MedComm (Beijing)* 2024;5:e792. <https://doi.org/10.1002/mco2.792>.
- Fuller H, Zhu Y, Nicholas J, Chatelaine HA, Drzymalla EM, Sarvestani AK, et al. Metabolomic epidemiology offers insights into disease aetiology. *Nat Metab* 2023;5:1656–72. <https://doi.org/10.1038/s42255-023-00903-x>.
- Stephenne X, Foretz M, Taleux N, van der Zon GC, Sokal E, Hue L, et al. Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status. *Diabetologia* 2011;54:3101–10. <https://doi.org/10.1007/s00125-011-2311-5>.
- Goel S, Singh R, Singh V, Singh H, Kumari P, Chopra H, et al. Metformin: Activation of 5' AMP-activated protein kinase and its emerging potential beyond anti-hyperglycemic action. *Front Genet* 2022;13. <https://doi.org/10.3389/fgene.2022.1022739>.
- Foretz M, Hébrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G, et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. *J Clin Invest* 2010;120:2355–69. <https://doi.org/10.1172/JCI40671>.
- Agius L, Ford BE, Chachra SS. The Metformin Mechanism on Gluconeogenesis and AMPK Activation: The Metabolite Perspective. *Int J Mol Sci* 2020;21. <https://doi.org/10.3390/ijms21093240>.
- Rena G, Hardie DG, Pearson ER. The mechanisms of action of metformin. *Diabetologia* 2017;60:1577–85. <https://doi.org/10.1007/s00125-017-4342-z>.
- Fontaine E. Metformin-Induced Mitochondrial Complex I Inhibition: Facts, Uncertainties, and Consequences. *Front Endocrinol (Lausanne)* 2018;9:753. <https://doi.org/10.3389/fendo.2018.00753>.
- Goswami S, Gong L, Giacomini K, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for SLC22A1. *Pharmacogenet Genomics* 2014;24:324–8. <https://doi.org/10.1097/FPC.0000000000000048>.
- Lozano E, Briz O, Macias R, Serrano MA, Marin JGG, Herraez E. Genetic Heterogeneity of SLC22 Family of Transporters in Drug Disposition. *J Pers Med* 2018;8:14. <https://doi.org/10.3390/jpm8020014>.
- Kawoosa F, Shah ZA, Masoodi SR, Amin A, Rasool R, Fazili KM, et al. Role of human organic cation transporter-1 (OCT-1/SLC22A1) in modulating the response to metformin in patients with type 2 diabetes. *BMC Endocr Disord* 2022;22:140. <https://doi.org/10.1186/s12902-022-01033-3>.
- Chen P, Cao Y, Chen S, Liu Z, Chen S, Guo Y. Association of SLC22A1, SLC22A2, SLC47A1, and SLC47A2 Polymorphisms with Metformin Efficacy in Type 2 Diabetic Patients. *Biomedicines* 2022;10. <https://doi.org/10.3390/biomedicines10102546>.
- Mueller NT, Differding MK, Zhang M, Maruthur NM, Juraschek SP, Miller ER, et al. Metformin Affects Gut Microbiome Composition and Function and Circulating Short-Chain Fatty Acids: A Randomized Trial. *Diabetes Care* 2021;44:1462–71. <https://doi.org/10.2337/dc20-2257>.
- Szymczak-Pajor I, Drzewoski J, Kozłowska M, Krekora J, Śliwińska A. The Gut Microbiota-Related Antihyperglycemic Effect of Metformin. *Pharmaceuticals* 2025;18:55. <https://doi.org/10.3390/ph18010055>.
- Elbere I, Silamikelis I, Dindune II, Kalnina I, Briviba M, Zaharenko L, et al. Baseline gut microbiome composition predicts metformin therapy short-term efficacy in newly

- diagnosed type 2 diabetes patients. *PLoS One* 2020;15:e0241338. <https://doi.org/10.1371/journal.pone.0241338>.
32. Zhang Y, Wang DD. Gut microbiome in type 2 diabetes: insights from metagenomics, multi-omics, and diet-microbe interactions. *Gut Microbes* 2026;18. <https://doi.org/10.1080/19490976.2026.2644682>.
 33. Dahabiyeh LA, Mujammami M, Arafat T, Benabdelkamel H, Alfadda AA, Abdel Rahman AM. A Metabolic Pattern in Healthy Subjects Given a Single Dose of Metformin: A Metabolomics Approach. *Front Pharmacol* 2021;12:705932. <https://doi.org/10.3389/fphar.2021.705932>.
 34. Yang Q, Cai Y, Guan Y, Wang Z, Guo S, Qiu S, et al. Metabolic phenotypes: Molecular bridges between health homeostasis and disease imbalance. *Comput Struct Biotechnol J* 2025;27:4710–9. <https://doi.org/10.1016/j.csbj.2025.10.057>.
 35. Hosseini SA, Valadbeigi H, Khoshnazar SM, Khoshnood S, Falahi S, Rezaee D, et al. Metformin as a Multifaceted Therapeutic Agent for Gastrointestinal Diseases: Mechanisms, Clinical Efficacy, and Future Directions. *Pharmacol Res Perspect* 2026;14:e70257. <https://doi.org/10.1002/prp2.70257>.
 36. Vo D-K, Trinh KTL. Emerging Biomarkers in Metabolomics: Advancements in Precision Health and Disease Diagnosis. *Int J Mol Sci* 2024;25. <https://doi.org/10.3390/ijms252313190>.
 37. Lozano E, Herraez E, Briz O, Robledo VS, Hernandez-Iglesias J, Gonzalez-Hernandez A, et al. Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacology. *Biomed Res Int* 2013;2013:692071. <https://doi.org/10.1155/2013/692071>.
 38. Sam WJ, Roza O, Hon YY, Alfaro RM, Calis KA, Reynolds JC, et al. Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance. *J Clin Pharmacol* 2017;57:219–29. <https://doi.org/10.1002/jcph.796>.
 39. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CCA, Bennett AJ, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. *Nat Genet* 2011;43:117–20. <https://doi.org/10.1038/ng.735>.
 40. Li JH, Perry JA, Jablonski KA, Srinivasan S, Chen L, Todd JN, et al. Identification of Genetic Variation Influencing Metformin Response in a Multiethnic Genome-Wide Association Study in the Diabetes Prevention Program (DPP). *Diabetes* 2023;72:1161–72. <https://doi.org/10.2337/db22-0702>.
 41. Hatmal MM, Abuyaman O, Al-Hatamleh MAI, Tayyem H, Olaimat AN, Mussa A, et al. Influence of OCT2 gene variants on metformin efficacy in type 2 diabetes: insights into pharmacogenomics and drug interactions. *J Transl Med* 2025;23:884. <https://doi.org/10.1186/s12967-025-06720-y>.
 42. Srinivasan S, Chen L, Udler M, Todd J, Kelsey MM, Haymond MW, et al. Initial Insights into the Genetic Variation Associated with Metformin Treatment Failure in Youth with Type 2 Diabetes. *Pediatr Diabetes* 2023;2023. <https://doi.org/10.1155/2023/8883199>.
 43. GoDARTS and UKPDS Diabetes Pharmacogenetics Study Group, Wellcome Trust Case Control Consortium 2, Zhou K, Bellenguez C, Spencer CCA, Bennett AJ, et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. *Nat Genet* 2011;43:117–20. <https://doi.org/10.1038/ng.735>.
 44. Anwardeen NR, Naja K, Elrayess MA. Advancements in precision medicine: multi-omics approach for tailored metformin treatment in type 2 diabetes. *Front Pharmacol* 2024;15. <https://doi.org/10.3389/fphar.2024.1506767>.
 45. Chen S, Gan D, Lin S, Zhong Y, Chen M, Zou X, et al. Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms. *Theranostics* 2022;12:2722–40. <https://doi.org/10.7150/thno.71360>.
 46. Ngcobo NN. Influence of Ageing on the Pharmacodynamics and Pharmacokinetics of Chronically Administered Medicines in Geriatric Patients: A Review. *Clin Pharmacokinet* 2025;64:335–67. <https://doi.org/10.1007/s40262-024-01466-0>.
 47. Ishida N, Harada S, Toki R, Hirata A, Matsumoto M, Miyagawa N, et al. Causal relationship between body mass index and insulin resistance: Linear and nonlinear Mendelian randomization study in a Japanese population. *J Diabetes Investig* 2025;16:1305–14. <https://doi.org/10.1111/jdi.14377>.
 48. Pu R, Shi D, Gan T, Ren X, Ba Y, Huo Y, et al. Effects of metformin in obesity treatment in different populations: a meta-analysis. *Ther Adv Endocrinol Metab* 2020;11:2042018820926000. <https://doi.org/10.1177/2042018820926000>.
 49. Hsu W-H, Hsiao P-J, Lin P-C, Chen S-C, Lee M-Y, Shin S-J. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. *Oncotarget* 2018;9:5416–23. <https://doi.org/10.18632/oncotarget.23387>.
 50. Martono DP, Hak E, Lambers Heerspink H, Wilffert B, Denig P. Predictors of HbA1c levels in patients initiating metformin. *Curr Med Res Opin* 2016;32:2021–8. <https://doi.org/10.1080/03007995.2016.1227774>.
 51. Chandra G, Lavikainen P, Siirtola P, Tamminen S, Ihlapathirana A, Laatikainen T, et al. Explainable Prediction of Long-Term Glycated Hemoglobin Response Change in Finnish Patients with Type 2 Diabetes Following Drug Initiation Using Evidence-Based Machine Learning Approaches. *Clin Epidemiol* 2025;Volume 17:225–40. <https://doi.org/10.2147/CLEP.S505966>.
 52. Gentilella R, Romera I, Nicolay C, Buzzetti R, Vázquez LA, Sesti G. Change in HbA1c Across the Baseline HbA1c Range in Type 2 Diabetes Patients Receiving Once-Weekly Dulaglutide Versus Other Incretin Agents. *Diabetes Ther* 2019;10:1113–25. <https://doi.org/10.1007/s13300-019-0625-3>.
 53. Ala M, Ala M. Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next? *ACS Pharmacol Transl Sci* 2021;4:1747–70. <https://doi.org/10.1021/acspstsci.1c00167>.
 54. Beger RD, Dunn W, Schmidt MA, Gross SS, Kirwan JA, Cascante M, et al. Metabolomics enables precision medicine: “A White Paper, Community Perspective”. *Metabolomics* 2016;12:149. <https://doi.org/10.1007/s11306-016-1094-6>.
 55. Kim HW. Metabolomic Approaches to Investigate the Effect of Metformin: An Overview. *Int J Mol Sci* 2021;22. <https://doi.org/10.3390/ijms221910275>.
 56. Alanazi S. Recent Advances in Liquid Chromatography-Mass Spectrometry (LC-MS) Applications in Biological and Applied Sciences. *Analytical Science Advances* 2025;6:e70024. <https://doi.org/10.1002/ansa.70024>.
 57. Emwas A-H, Roy R, McKay RT, Tenori L, Saccenti E, Gowda GAN, et al. NMR Spectroscopy for Metabolomics Research. *Metabolites* 2019;9. <https://doi.org/10.3390/metabo9070123>.
 58. Tobias DK, Mora S, Verma S, Lawler PR. Altered branched chain amino acid metabolism: toward a unifying cardiometabolic hypothesis. *Curr Opin Cardiol* 2018;33:558–64. <https://doi.org/10.1097/HCO.0000000000000552>.
 59. Zhao X, Zhang X, Pei J, Liu Y, Niu W, Sun H. Targeting BCAA metabolism to potentiate metformin’s therapeutic efficacy in the treatment of diabetes in mice. *Diabetologia* 2023;66:2139–53. <https://doi.org/10.1007/s00125-023-05985-6>.
 60. Dahabiyeh LA, Mujammami M, AlMalki RH, Arafat T, Benabdelkamel H, Alfadda AA, et al. Lipids Alterations Associated with Metformin in Healthy Subjects: An Investigation Using Mass Spectrometry Shotgun Approach. *Int J Mol Sci* 2022;23. <https://doi.org/10.3390/ijms231911478>.
 61. Hammad SM, Lopes-Virella MF. Circulating Sphingolipids in Insulin Resistance, Diabetes and Associated Complications. *Int J Mol Sci* 2023;24. <https://doi.org/10.3390/ijms241814015>.
 62. Dobosz AM, Krogulec E, Stefanowski N, Kendziorek M, Lebiedzinska-Arciszewska M, Wieckowski MR, et al. Metformin

- promotes lipid droplet-mitochondria coupling and improves insulin secretion in pancreatic β -cells exposed to lipotoxicity. *Biochim Biophys Acta Mol Cell Biol Lipids* 2025;1870:159664. <https://doi.org/10.1016/j.bbalip.2025.159664>.
63. Liu J, Tan Y, Cheng H, Zhang D, Feng W, Peng C. Functions of Gut Microbiota Metabolites, Current Status and Future Perspectives. *Aging Dis* 2022;13:1106–26. <https://doi.org/10.14336/AD.2022.0104>.
 64. Du Y, He C, An Y, Huang Y, Zhang H, Fu W, et al. The Role of Short Chain Fatty Acids in Inflammation and Body Health. *Int J Mol Sci* 2024;25. <https://doi.org/10.3390/ijms25137379>.
 65. Kiran M, Xie Y, Anjum N, Ball G, Pierscionek B, Russell D. Machine learning and artificial intelligence in type 2 diabetes prediction: a comprehensive 33-year bibliometric and literature analysis. *Front Digit Health* 2025;7:1557467. <https://doi.org/10.3389/fdgh.2025.1557467>.
 66. Alyatimi A, Iqbal MA, Chung V, Zandavi SM, Anaissi A. Transforming multi-omics data into images for disease classification: A review of techniques and tools. *J Pathol Inform* 2026;20:100543. <https://doi.org/10.1016/j.jpi.2026.100543>.
 67. Savargiv M, Masoumi B, Keyvanpour MR. A New Random Forest Algorithm Based on Learning Automata. *Comput Intell Neurosci* 2021;2021:5572781. <https://doi.org/10.1155/2021/5572781>.
 68. Garg S, Kitchen R, Gupta R, Pearson E. Applications of AI in Predicting Drug Responses for Type 2 Diabetes. *JMIR Diabetes* 2025;10:e66831. <https://doi.org/10.2196/66831>.
 69. Suárez CA, Castro M, Leon M, Martin-Barreiro C, Liut M. Improving SVM performance through data reduction and misclassification analysis with linear programming. *Complex & Intelligent Systems* 2025;11:356. <https://doi.org/10.1007/s40747-025-01989-4>.
 70. Huang S, Cai N, Pacheco PP, Narrandes S, Wang Y, Xu W. Applications of Support Vector Machine (SVM) Learning in Cancer Genomics. *Cancer Genomics Proteomics* 2018;15:41–51. <https://doi.org/10.21873/cgp.20063>.
 71. Wang Y, Liu L, Wang C. Trends in using deep learning algorithms in biomedical prediction systems. *Front Neurosci* 2023;17:1256351. <https://doi.org/10.3389/fnins.2023.1256351>.
 72. Linardatos P, Papastefanopoulos V, Kotsiantis S. Explainable AI: A Review of Machine Learning Interpretability Methods. *Entropy (Basel)* 2020;23. <https://doi.org/10.3390/e23010018>.
 73. Qiao Y, Zhou H, Liu Y, Chen R, Zhang X, Nie S, et al. A multi-modal fusion model with enhanced feature representation for chronic kidney disease progression prediction. *Brief Bioinform* 2024;26. <https://doi.org/10.1093/bib/bbaf003>.
 74. Mohr AE, Ortega-Santos CP, Whisner CM, Klein-Seetharaman J, Jasbi P. Navigating Challenges and Opportunities in Multi-Omics Integration for Personalized Healthcare. *Biomedicines* 2024;12. <https://doi.org/10.3390/biomedicines12071496>.
 75. Manzoor F, Gupta V, Pinky L, Wang Z, Chen Z, Deng Y, et al. A Systematic Review of Multimodal Deep Learning and Machine Learning Fusion Techniques for Prostate Cancer Classification. *MedRxiv* 2025. <https://doi.org/10.1101/2025.08.07.25333235>.
 76. AlSekait DM, Zakariah M, Amin SU, Dubey P, Khan ZI. Using convolutional neural networks with late fusion to predict heart disease. *Sci Rep* 2025;15:41260. <https://doi.org/10.1038/s41598-025-25100-6>.
 77. Boie SD, Giesa N, Sekutowicz M, Zhumagambetov R, Haufe S, Grünwald E, et al. Multimodal data for predictive medicine: algorithmic fusion of clinical data in anesthesiology and intensive care. *Front Med (Lausanne)* 2026;13:1746867. <https://doi.org/10.3389/fmed.2026.1746867>.
 78. Gadzicki K, Khamsehashari R, Zetsche C. Early vs Late Fusion in Multimodal Convolutional Neural Networks. 2020 IEEE 23rd International Conference on Information Fusion (FUSION), IEEE; 2020, p. 1–6. <https://doi.org/10.23919/FUSION45008.2020.9190246>.
 79. Guarrasi V, Aksu F, Caruso CM, Di Feola F, Rofena A, Ruffini F, et al. A systematic review of intermediate fusion in multimodal deep learning for biomedical applications. *Image Vis Comput* 2025;158:105509. <https://doi.org/10.1016/j.imavis.2025.105509>.
 80. Viswan V, Shaffi N, Malathy E, Chemmalar Selvi G, Kavitha BR, Abdesselam A, et al. Multimodal fusion and explainability of artificial intelligence models in Alzheimer's Disease detection. *Brain Inform* 2026;13:5. <https://doi.org/10.1186/s40708-025-00291-w>.
 81. Lakshmi V, Pushpa B. Explainable multimodal deep learning using cross-attention fusion of ultrasound and clinical features for PCOS classification. *Discover Computing* 2026;29:7. <https://doi.org/10.1007/s10791-025-09901-x>.
 82. Venkatachalapathy P, Padhilahouse S, Sellappan M, Subramanian T, Kurian SJ, Miraj SS, et al. Pharmacogenomics and Personalized Medicine in Type 2 Diabetes Mellitus: Potential Implications for Clinical Practice. *Pharmacogenomics Pers Med* 2021;14:1441–55. <https://doi.org/10.2147/PGPM.S329787>.
 83. Phate SD, Daswani BR, Mishra DN, Joshi KS. Genetic analysis of SLC47A1, SLC22A1, SLC22A2, ATM gene polymorphisms among diabetics in an Indian population. *Int J Basic Clin Pharmacol* 2020;9:891. <https://doi.org/10.18203/2319-2003.ijbcp20202189>.
 84. Altall RM, Qusti SY, Filimban N, Alhozali AM, Alotaibi NA, Dallol A, et al. SLC22A1 And ATM Genes Polymorphisms Are Associated With The Risk Of Type 2 Diabetes Mellitus In Western Saudi Arabia: A Case-Control Study. *Appl Clin Genet* 2019;12:213–9. <https://doi.org/10.2147/TACG.S229952>.
 85. Han Y-C, Shearer J, Mu C, Slater DM, Tough SC, Duggan GE. Comparative analysis of machine learning techniques in metabolomic-based preterm birth prediction. *Comput Struct Biotechnol J* 2025;27:3240–50. <https://doi.org/10.1016/j.csbj.2025.07.010>.
 86. Yuan B, Liu C, Chen S, Chu J, Yang Y, Pan Y, et al. Metabolomics-driven, data-augmented machine learning for predicting toxicity of microplastic mixtures. *Ecotoxicol Environ Saf* 2026;312:119944. <https://doi.org/10.1016/j.ecoenv.2026.119944>.
 87. Stolaki E V, Psatha K, Aivaliotis M. Metabolomics and Pharmacometabolomics: Advancing Precision Medicine in Drug Discovery and Development. *Metabolites* 2025;15. <https://doi.org/10.3390/metabo15110750>.
 88. Pan S, Yin L, Liu J, Tong J, Wang Z, Zhao J, et al. Metabolomics-driven approaches for identifying therapeutic targets in drug discovery. *MedComm (Beijing)* 2024;5. <https://doi.org/10.1002/mco2.792>.
 89. Oravilahti A, Vangipurapu J, Laakso M, Fernandes Silva L. Metabolomics-Based Machine Learning for Predicting Mortality: Unveiling Multisystem Impacts on Health. *Int J Mol Sci* 2024;25. <https://doi.org/10.3390/ijms252111636>.
 90. Sanches PHG, de Melo NC, Porcari AM, de Carvalho LM. Integrating Molecular Perspectives: Strategies for Comprehensive Multi-Omics Integrative Data Analysis and Machine Learning Applications in Transcriptomics, Proteomics, and Metabolomics. *Biology (Basel)* 2024;13. <https://doi.org/10.3390/biology13110848>.
 91. Hu C, Jia W. Multi-omics profiling: the way towards precision medicine in metabolic diseases. *J Mol Cell Biol* 2021;13:576–93. <https://doi.org/10.1093/jmcb/mjab051>.
 92. Zhang J, Che Y, Liu R, Wang Z, Liu W. Deep learning-driven multi-omics analysis: enhancing cancer diagnostics and therapeutics. *Brief Bioinform* 2025;26. <https://doi.org/10.1093/bib/bbaf440>.
 93. Muthoni D. M. Artificial Intelligence and Big Data in Predicting and Managing Obesity-Associated Diabetes. *Idosr Journal of Biology, Chemistry and Pharmacy* 2026;11:15–21. <https://doi.org/10.59298/IDOSR/JBCP/26/102.1521>.
 94. Wörheide MA, Krumsiek J, Kastenmüller G, Arnold M. Multi-omics integration in biomedical research - A metabolomics-centric review. *Anal Chim Acta* 2021;1141:144–62. <https://doi.org/10.1016/j.aca.2020.10.038>.

95. Chourib I. Missing Data Handling: A Comprehensive Review, Taxonomy, and Comparative Evaluation. *Journal of Computer and Communications* 2025;13:81–102. <https://doi.org/10.4236/jcc.2025.136006>.
96. Kumar S, Pal A, Chatterjee S. Unlocking the potential of computational phenotypic drug discovery: methods, challenges, and future directions. *NPJ Syst Biol Appl* 2026;12:46. <https://doi.org/10.1038/s41540-026-00676-5>.
97. Maruotto I, Ciliberti FK, Gargiulo P, Recenti M. Feature Selection in Healthcare Datasets: Towards a Generalizable Solution. *Comput Biol Med* 2025;196:110812. <https://doi.org/10.1016/j.combiomed.2025.110812>.

How to cite this article: K. Chandramohan, R. Nepolean, V. Balaji, D. Anbarasu, N. Jayaram. Integrative Machine Learning Approaches for Predicting Metformin Response in Type 2 Diabetes: A Multi-Omics Perspective. *Indian J Pharm Drug Studies*. 2026; 5(2):47-58.

Funding: None;

Conflicts of Interest: None Stated